Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: Implications for primary pulmonary hypertension

Circulation

Volumn 100, Issue 8, 1999, Pages 869-875

  Rothman, Richard B ^a   Ayestas, Mario A ^a   Dersch, Christina M ^a   Baumann, Michael H ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Drugs; Hypertension; Obesity; Pulmonary heart disease

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMINOREX; AMPHETAMINE; ANOREXIGENIC AGENT; CHLORPHENTERMINE; CLOMIPRAMINE; COCAINE; COCAINE DERIVATIVE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; FENFLURAMINE; FLUOXETINE; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ADVERSE DRUG REACTION; AMINE TRANSPORT; ANIMAL TISSUE; ARTICLE; BRAIN; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG UPTAKE; INTRAVENOUS DRUG ADMINISTRATION; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT;

EID: 0033600538     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.8.869     Document Type: Article

References (46)

1. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther. 1992;51:642-646.
2. Rothman RB, Elmer GI, Shippenberg TS, Rea W, Baumann MH. Phentermine and fenfluramine: preclinical studies in animal models of cocaine addiction. Ann N Y Acad Sci. 1998;844:59-74.
3. Abenhaim L, Monde Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of pulmonary hypertension. N Engl J Med. 1996;335:609-616.
4. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
5. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336: 111-117.
6. Gurtner HP. Aminorex pulmonary hypertension. In: Fishman AP, ed. The Pulmonary Circulation: Normal and Abnormal. Philadelphia, Pa: University of Pennsylvania Press; 1990:397-411.
7. Backmann R, Dengler H, Gahl K, Greiser E, Jesdinsky HJ, Loogen F. Primary pulmonary hypertension: report of the Commission of the German Society for Research on Blood Circulation. Verh Dtsch Ges Kreislaufforsch. 1972;38:134-141.
8. Schnabel KF, Schulz V, Busch S, Just H. Drug-induced primary vascular pulmonary hypertension. Med Welt. 1976;27:1300-1303.
9. Lullmann H, Parwaresch MR, Sattler M, Seiler KU, Siegfriedt A. The effects of anorectic agents on the pulmonary pressure and morphology of rat lungs after chronic administration. Arzneimittelforschung. 1972;22: 2096-2099.
10. Herve P, Launay J-M. Scrobohaci M-L, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99: 249-254.
11. Stubbs EG, Budden SS, Jackson RH, Terdal LG, Ritvo ER. Effects of fenfluramine on eight outpatients with the syndrome of autism. Dev Med Child Neurol. 1986;28:229-235.
12. Celada P, Martin F, Artigas F. Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci. 1994;55:1237-1243.
13. Martin F, Artigas F. Simultaneous effects of p-chloroamphetamine, d-fenfluramine, and reserpine on free and stored 5-hydroxytryptamine in brain and blood. J Neurochem. 1992;59:1138-1144.
14. Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, Archer SL. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 1996;94: 2216-2220.
15. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci U S A. 1993;90:2542-2546.
16. Gillis CN. Peripheral metabolism of serotonin. In: Vanhoutte PM, ed. Serotonin and the Cardiovascular System. New York, NY: Raven Press; 1985:27-36.
17. Berger UV, Gu XF, Azmitia EC. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol. 1992;215:153-160.
18. Baumann MH, Char GU, de Costa BR, Rice KC, Rothman RB. GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther. 1994;271: 1216-1222.
19. Rothman RB, Lewis B, Dersch CM, Xu H, Radesca L, de Costa BR, Rice KC, Kilburn RB, Akunne HC, Pert A. Identification of a GBR12935 homolog, LR1111, which is over 4000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters. Synapse. 1993;14:34-39.
20. 125I]RTI-55. J Pharmacol Exp Ther. 1994;270: 296-309.
21. Cox RH Jr, Maickel RP. Comparison of anorexigenic and behavioral potency of phenylethylamines. J Pharmacol Exp Ther. 1972;181:1-9.
22. Young R. Aminorex produces stimulus effects similar to amphetamine and unlike those of fenfluramine. Pharmacol Biochem Behav. 1992;42: 175-178.
23. Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, Amara SG. Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci. 1997;17:960-974.
24. Wayment H, Meiergerd SM, Schenk JO. Relationships between the catechol substrate-binding site and amphetamine, cocaine, and mazindol binding-sites in a kinetic-model of the striatal transporter of dopamine in-vitro. J Neurochem. 1998;70:1941-1949.
25. Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnick G. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol Pharmacol. 1993;44: 1227-1231.
26. Crespi D. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol. 1997;121: 1735-1743.
27. Matecka D, Lewis D, Rothman RB, Dersch CM, Wojnicki FH, Glowa JR, DeVries AC, Pert A, Rice KC. Heteroaromatic analogs of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors. J Med Chem. 1997;40:705-716.
28. 3H]Cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation by paroxetine. Neurochem Res. 1992;17:1275-1283.
29. 3H]GBR 12935 binding in vitro to rat striatal membranes: labeling of the dopamine uptake complex. J Neurochem. 1987;48:1887-1896.
30. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA. 1992;89: 7782-7785.
31. 3H]WIN 35,428 binding. Naunyn Schmiedebergs Arch Pharmacol. 1997;355:64-73.
32. Wall SC, Gu H, Rudnick G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol. 1995;47:544-550.
33. McCann UD, Seiden LS, Rubin LJ, Ricaurte GA. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: a systematic review of the literature. JAMA. 1997;278: 666-672.
34. Lee SL, Wang WW, Lanzillo JJ, Fanburg BL. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol. 1994;266:L46-L52.
35. Mehendale HM. Pulmonary disposition and effects of drugs on pulmonary removal of endogenous substances. Fed Proc. 1984;43:2586-2591.
36. Seiler KU, Wassermann O. Evidence for an unusual distribution of chlorphentermine in vivo: an autoradiographic study in mice. Naunyn Schmiedebergs Arch Pharmacol. 1974;282:113-122.
37. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH, Arnold ND, Siemieniak DR, Wheeler L, Phillips JA, Newman JH, Conneally PM, Ginsburg D, Loyd JE. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet. 1997;15: 277-280.
38. Cozzi NV, Frescas S, Marona-Lewicka D, Huang X, Nichols DE. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacol Biochem Behav. 1998;59:709-715.
39. Baumann MH, Rutter JJ, Auerbach SB. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats. Neuropharmacology. 1993;32:1381-1386.
40. Baumann MH, Ayestas MA, Rothman RB. Effects of d-fenfluramine and m-chlorophenylpiperazine on acute 5-HT release and long-term 5-HT depletion in rat brain. Soc Neurosci Abstr. 1994;24:1028. Abstract.
41. Ulrichsen J, Partilla JS, Dax EM. Long-term administration of m-chlorophenylpiperazine (mCPP) to rats induces changes in serotonin receptor binding, dopamine levels and locomotor activity without altering prolactin and corticosterone secretion. Psychopharmacology (Berl). 1992; 107:229-235.
42. 3H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. Life Sci. 1993;53:PL267-PL272.
43. 2+ dependence of the amphetamine, nomifensine, and Lu 19-005 effect on in vivo dopamine transmission. Eur J Pharmacol. 1989;166:261-269.
44. Rothman RB, Ayestas M, Baumann MH. Phentermine pretreatment antagonizes the cocaine-induced rise in mesolimbic dopamine. Neuroreport. 1996;8:7-9.
45. Shoaib M, Baumann MH, Rothman RB, Goldberg SR, Schindler CW. Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats. Psychopharmacology (Berl). 1997;131:296-306.
46. Abenhaim L, Rich S, Benichou J, Begaud B. Primary pulmonary hypertension and anorectic drugs. N Engl J Med. 1999;340:482-483.